Designing Pregnancy Centered Medications: Drugs Which Do Not Cross the Human Placenta

C. Gedeon; G. Koren

doi:10.1016/j.placenta.2005.09.001

Designing Pregnancy Centered Medications: Drugs Which Do Not Cross the Human Placenta

C. Gedeon, G. Koren

Research output: Contribution to journal › Article › peer-review

100 Scopus citations

Abstract

This review considers and evaluates the role of placental transporters (multidrug resistance proteins, P-glycoprotein and breast cancer resistance protein) in the uptake and efflux of drugs used in pregnancy. The effect of placental transporters in effluxing drugs such as glyburide and numerous protease inhibitors from the fetal circulation offers the potential to manipulate the passage of drugs across the placenta. The discovery of the interactions of these drugs with placental transporters may provide a novel framework for future drug development in which medications can be designed to control the degree of fetal exposure and thus prevent fetal risk.

Original language	English
Pages (from-to)	861-868
Number of pages	8
Journal	Placenta
Volume	27
Issue number	8
DOIs	https://doi.org/10.1016/j.placenta.2005.09.001
State	Published - Aug 2006
Externally published	Yes

Keywords

ABC transporters
Glyburide
Human placenta
Protease and reverse transcriptase inhibitors

Access to Document

10.1016/j.placenta.2005.09.001

Cite this

@article{c9d2577ea60645f2b0a5dd7baba4792a,

title = "Designing Pregnancy Centered Medications: Drugs Which Do Not Cross the Human Placenta",

abstract = "This review considers and evaluates the role of placental transporters (multidrug resistance proteins, P-glycoprotein and breast cancer resistance protein) in the uptake and efflux of drugs used in pregnancy. The effect of placental transporters in effluxing drugs such as glyburide and numerous protease inhibitors from the fetal circulation offers the potential to manipulate the passage of drugs across the placenta. The discovery of the interactions of these drugs with placental transporters may provide a novel framework for future drug development in which medications can be designed to control the degree of fetal exposure and thus prevent fetal risk.",

keywords = "ABC transporters, Glyburide, Human placenta, Protease and reverse transcriptase inhibitors",

author = "C. Gedeon and G. Koren",

note = "Funding Information: Supported by a grant by the Canadian Institute for Health research. ",

year = "2006",

month = aug,

doi = "10.1016/j.placenta.2005.09.001",

language = "אנגלית",

volume = "27",

pages = "861--868",

journal = "Placenta",

issn = "0143-4004",

publisher = "W.B. Saunders Ltd",

number = "8",

}

TY - JOUR

T1 - Designing Pregnancy Centered Medications

T2 - Drugs Which Do Not Cross the Human Placenta

AU - Gedeon, C.

AU - Koren, G.

N1 - Funding Information: Supported by a grant by the Canadian Institute for Health research.

PY - 2006/8

Y1 - 2006/8

N2 - This review considers and evaluates the role of placental transporters (multidrug resistance proteins, P-glycoprotein and breast cancer resistance protein) in the uptake and efflux of drugs used in pregnancy. The effect of placental transporters in effluxing drugs such as glyburide and numerous protease inhibitors from the fetal circulation offers the potential to manipulate the passage of drugs across the placenta. The discovery of the interactions of these drugs with placental transporters may provide a novel framework for future drug development in which medications can be designed to control the degree of fetal exposure and thus prevent fetal risk.

AB - This review considers and evaluates the role of placental transporters (multidrug resistance proteins, P-glycoprotein and breast cancer resistance protein) in the uptake and efflux of drugs used in pregnancy. The effect of placental transporters in effluxing drugs such as glyburide and numerous protease inhibitors from the fetal circulation offers the potential to manipulate the passage of drugs across the placenta. The discovery of the interactions of these drugs with placental transporters may provide a novel framework for future drug development in which medications can be designed to control the degree of fetal exposure and thus prevent fetal risk.

KW - ABC transporters

KW - Glyburide

KW - Human placenta

KW - Protease and reverse transcriptase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=33745217631&partnerID=8YFLogxK

U2 - 10.1016/j.placenta.2005.09.001

DO - 10.1016/j.placenta.2005.09.001

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16313957

AN - SCOPUS:33745217631

SN - 0143-4004

VL - 27

SP - 861

EP - 868

JO - Placenta

JF - Placenta

IS - 8

ER -

Designing Pregnancy Centered Medications: Drugs Which Do Not Cross the Human Placenta

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this